Atrophic gastritis Medical Services in China

Atrophic gastritis is a chronic inflammatory condition of the gastric mucosa characterized by progressive loss of gastric glandular cells, replacement with intestinal-type epithelium (intestinal metaplasia) and fibrous tissue, and consequent reduction in gastric acid and enzyme secretion. It represents an advanced stage of chronic gastritis, often developing over years or decades. Pathogenesis is multifactorial: the most common cause is persistent Helicobacter pylori infection, which triggers chronic immune-mediated inflammation leading to parietal and chief cell atrophy. Autoimmune atrophic gastritis—less common but clinically significant—involves autoantibodies against gastric parietal cells and intrinsic factor, resulting in achlorhydria, vitamin B12 deficiency, and increased risk of pernicious anemia and gastric neuroendocrine tumors. Other contributors include long-term use of proton pump inhibitors (though causality remains debated), bile reflux, smoking, excessive alcohol consumption, and genetic predisposition (e.g., polymorphisms in IL-1β and TNF-α genes). Epidemiologically, atrophic gastritis affects approximately 10–20% of adults globally, with prevalence rising sharply with age—reaching 30–50% in individuals over 60 years. Geographic variation is notable: higher rates are observed in East Asia (especially Japan and China), Eastern Europe, and Latin America, correlating with H. pylori endemicity and dietary factors such as high salt intake and low fruit/vegetable consumption. Risk factors include H. pylori seropositivity (odds ratio >5), autoimmune disorders (e.g., Hashimoto’s thyroiditis, type 1 diabetes), family history of gastric cancer, smoking (2–3× increased risk), and prolonged hypochlorhydria. Clinically, many patients remain asymptomatic for years; when symptoms occur, they are often nonspecific—early satiety, postprandial fullness, epigastric discomfort, mild nausea, or iron-deficiency anemia due to impaired iron absorption. Vitamin B12 deficiency may manifest as fatigue, glossitis, peripheral neuropathy, or cognitive changes. Importantly, atrophic gastritis is a precancerous condition: it confers a 4–6× increased relative risk of gastric adenocarcinoma, particularly when accompanied by intestinal metaplasia and dysplasia. Surveillance endoscopy with targeted biopsies is recommended for high-risk patients. Quality of life impact is frequently underestimated: chronic dyspeptic symptoms reduce daily functioning and nutritional status; B12 deficiency impairs energy metabolism and neurological health; anxiety around cancer risk contributes to psychological distress; and dietary restrictions (e.g., avoidance of spicy or acidic foods) may limit social eating and cultural participation. Early diagnosis via upper endoscopy with histopathological assessment—and timely management of underlying causes—is critical to mitigate complications and preserve gastric function.

Atrophic gastritis is a chronic inflammatory condition characterized by progressive loss of gastric glandular cells, replacement with intestinal or fibrous tissue, and associated hypochlorhydria or achlorhydria. It is commonly linked to long-standing Helicobacter pylori infection, autoimmune mechanisms (particularly in autoimmune metaplastic atrophic gastritis), aging, and environmental factors such as smoking or excessive alcohol intake. Left untreated, it may predispose to gastric intestinal metaplasia, dysplasia, and ultimately gastric adenocarcinoma—underscoring the necessity for timely, evidence-based management. Treatment is primarily conservative and tailored to etiology, symptom burden, histopathological severity, and risk stratification.

Conservative treatment forms the cornerstone of management and emphasizes lifestyle modification, dietary optimization, and surveillance. Patients are advised to eliminate known gastric irritants—including tobacco, alcohol, nonsteroidal anti-inflammatory drugs (NSAIDs), and highly processed or excessively spicy foods. A nutrient-dense, low-acid, easily digestible diet is recommended: small, frequent meals rich in antioxidants (e.g., leafy greens, berries, cruciferous vegetables) and B12-fortified foods or supplements (especially in cases of concomitant pernicious anemia). Avoidance of prolonged fasting helps mitigate bile reflux-related mucosal injury. Regular physical activity and stress reduction techniques (e.g., mindfulness-based stress reduction) are encouraged to modulate neuroendocrine influences on gastric motility and inflammation. Importantly, conservative care includes structured endoscopic surveillance: patients with extensive atrophy (OLGA/OLGIM stage III–IV) or intestinal metaplasia undergo high-definition white-light or chromoendoscopy with targeted biopsies every 1–3 years, depending on histologic risk profile and regional guidelines.

Pharmacotherapy is directed toward underlying causes and sequelae. First-line therapy for H. pylori–positive atrophic gastritis is quadruple eradication therapy—typically bismuth-based (e.g., bismuth subcitrate potassium 240 mg twice daily), a proton pump inhibitor (PPI) (e.g., esomeprazole 40 mg twice daily), tetracycline 500 mg four times daily, and metronidazole 500 mg three times daily—for 10–14 days. Confirmation of eradication via stool antigen test or urea breath test is mandatory ≥4 weeks post-therapy. In autoimmune atrophic gastritis, PPIs may be used judiciously for symptomatic relief of reflux or dyspepsia but are avoided long-term unless clinically indicated, given concerns about rebound hypergastrinemia and potential mucosal effects in hypochlorhydric states. Vitamin B12 replacement is essential in patients with documented deficiency or intrinsic factor antibodies; intramuscular cyanocobalamin (1000 µg monthly after initial loading doses) or high-dose oral supplementation (1000–2000 µg daily) is effective when absorption capacity permits. Iron supplementation (ferrous sulfate or ferric maltol) is instituted for iron-deficiency anemia secondary to chronic gastric bleeding or impaired absorption. Emerging adjunctive agents under investigation include probiotics (e.g., Lactobacillus reuteri DSM17938) to modulate gastric microbiota and reduce oxidative stress, and carotenoid-rich nutraceuticals (e.g., lycopene, beta-carotene) showing promise in preclinical models for attenuating epithelial atrophy.

Surgical intervention has no role in routine management of atrophic gastritis itself. However, surgery becomes necessary in rare, advanced complications: endoscopically unresectable high-grade dysplasia or early gastric cancer arising in the context of longstanding atrophy warrants laparoscopic or open gastrectomy with D2 lymphadenectomy per Japanese Gastric Cancer Association (JGCA) or European Society for Medical Oncology (ESMO) guidelines. Endoscopic submucosal dissection (ESD) is preferred for well-differentiated, superficial (T1a) neoplasms confined to the mucosa without ulceration or lymphovascular invasion. Prophylactic total gastrectomy is not indicated—even in severe atrophy—due to lack of mortality benefit and substantial morbidity (e.g., dumping syndrome, nutritional deficiencies, bone demineralization). Surgical decisions require multidisciplinary review involving gastroenterologists, gastrointestinal pathologists, and upper GI surgeons.

China offers distinct advantages in the comprehensive management of atrophic gastritis. First, nationwide integration of AI-assisted endoscopic diagnosis enables real-time detection and classification of atrophic patterns (e.g., using the Linked Color Imaging [LCI] + BLI system with deep learning algorithms trained on >50,000 annotated gastric images), significantly improving interobserver agreement and early lesion identification. Second, China’s large-scale prospective cohort studies—such as the China Kadoorie Biobank and the Shanghai Gastric Precancerous Conditions Cohort—have generated robust, population-specific risk prediction models incorporating serologic pepsinogen I/II ratio, gastrin-17, and anti-H. pylori IgG titers, enabling precision risk stratification. Third, standardized national protocols (e.g., the 2023 Chinese Society of Gastroenterology Consensus on Chronic Atrophic Gastritis) harmonize biopsy mapping (Sydney System + extended antrum-corpus-body sampling), histopathological grading (OLGIM staging), and follow-up intervals across tertiary centers. Fourth, cost-effective access to high-quality generic PPIs, bismuth formulations, and parenteral B12 ensures adherence in diverse socioeconomic settings. Finally, traditional Chinese medicine (TCM) integrative approaches—such as modified Weiling Decoction (containing Poria, Atractylodes, and Pinellia)—are increasingly incorporated into clinical trials demonstrating synergistic anti-inflammatory and mucosal repair effects when combined with standard Western regimens.

Recovery and long-term health maintenance emphasize patient empowerment and continuity of care. Patients should undergo annual serum pepsinogen I/II ratio and gastrin-17 testing to monitor progression; persistent low pepsinogen I (<30 µg/L) and elevated gastrin-17 (>10 pmol/L) warrant intensified surveillance. Nutritional counseling with registered dietitians specializing in gastrointestinal disorders is strongly recommended to prevent micronutrient deficiencies (B12, iron, folate, vitamin D, calcium). Psychological support is integral—studies show anxiety related to cancer risk correlates with symptom amplification and reduced quality of life; cognitive behavioral therapy (CBT) modules delivered via telehealth platforms have demonstrated efficacy in Chinese cohorts. Patients must understand that atrophic gastritis is not curable but controllable: stabilization or even partial histologic regression has been documented following sustained H. pylori eradication and antioxidant supplementation. Adherence to scheduled endoscopies—not symptom-driven evaluation—is critical. Finally, first-degree relatives of patients with gastric cancer and atrophy should be offered screening endoscopy starting at age 40, reflecting China’s familial risk mitigation strategy. With coordinated, multidisciplinary, and culturally adapted care, most patients achieve stable disease, preserved gastric function, and markedly reduced neoplastic risk over decades.